Q-omics provides the consensus-scored NTAQ1 profile across patient tissues and cancer cell-line models. NTAQ1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NTAQ1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, NTAQ1 RNA expression shows 19,378 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where NTAQ1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NTAQ1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NTAQ1 survival associations across molecular data types. NTAQ1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NTAQ1 RNA expression–survival associations across cancer types. High NTAQ1 expression shows unfavorable associations in ACC, LIHC, KIRP, SCLC, UVM and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NTAQ1 RNA expression.
This table summarizes NTAQ1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NTAQ1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NTAQ1 shows higher tumor expression in HNSC, COAD, LIHC, LUAD, LUSC and BLCA. The HNSC box plot shows higher NTAQ1 RNA expression in tumor versus normal tissue (log2 FC = +0.956, t-test p < 0.001).
This table shows molecular features associated with NTAQ1 in patient tissues and cancer cell lines. In patient samples, NTAQ1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NTAQ1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
